Board Changes

Phytopharm PLC
05 September 2006



Board Changes


GODMANCHESTER, Cambridgeshire, U.K. (5th September 2006) - Phytopharm plc (LSE:
PYM; NASDAQBB: PHYOF; PHYOY) ('Phytopharm') announces that Gordon Stevens
(non-executive Chairman) and Trevor Flanagan (non-executive Director) have today
retired from the Board and that Paul Whitney (currently Deputy Chairman) has
today stepped up to the role of non-executive Chairman.


This reorganisation follows the recent appointments of two non-executive
Directors - Dr Peter Blower, former Director of New Neuroscience products at
SmithKline Beecham, and Sandy Morrison, former CEO of Lipton Ltd, a Unilever
subsidiary.


Gordon Stevens said; 'I am pleased to be handing over the Chairman's role to
Paul Whitney. Phytopharm has an excellent team, and with the recent strong
additions to the Board I believe the Company is well placed for much-deserved
success.'


Paul Whitney said; 'On behalf of the Board of Phytopharm and myself personally,
I would like to thank Gordon and Trevor for their enthusiasm and energy over the
last 10 years.  We wish them well in their future activities.'




NOTES TO EDITORS


Phytopharm plc

Phytopharm is a pharmaceutical company with a plant extract division. The
pharmaceutical division is dedicated to the discovery and development of single
chemicals as prescription medicines and the plant extract division is focussed
on the development of plant extracts as functional foods and veterinary
products.



More information concerning Phytopharm's activities can be found on its website
at http://www.phytopharm.com


Company Contact:                               U.K. Investor Relations Contact:
Phytopharm plc                                 Financial Dynamics
Dr Richard Dixey                               David Yates / Ben Atwell
[phone]                                [phone]
Dr Daryl Rees
[phone]
www.phytopharm.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange